Product Program year 2019 Source: CMS Open Payments

Vancomycin

Drug Injection/Antibacterial

NDC 70594-043-02

Open in the dashboard

General payments

$16,099

24 payments

Research payments

$0

0 payments

Through program year 2019, $16,099 in general payments and $0 in research payments were reported against Vancomycin (Injection/Antibacterial).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2019 General $16,099 24

Breakdown

Who paid General payments · program year 2019
  1. Xellia Pharmaceuticals $16,099 24 payments
Top recipients General payments · program year 2019
  1. Andrew Shorr Pulmonary Disease · Washington, DC $4,603 29% · 6 payments
  2. Markos Kashiouris Critical Care Medicine · Falls Church, VA $3,635 23% · 3 payments
  3. Keith Kaye Infectious Disease · Ann Arbor, MI $3,614 22% · 6 payments
  4. George Sakoulas Infectious Disease · San Diego, CA $3,326 21% · 6 payments
  5. Bhagyashri Navalkele Infectious Disease · Atlanta, GA $781 5% · 2 payments

The top 5 of 6 recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Infectious Disease Internal Medicine $7,860 49% · 4 practitioners
  2. Pulmonary Disease Internal Medicine $4,603 29% · 1 practitioner
  3. Critical Care Medicine Internal Medicine $3,635 23% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2019
  1. District of Columbia $4,603 29% · 1 recipient
  2. Virginia $3,635 23% · 1 recipient
  3. Michigan $3,614 22% · 1 recipient
  4. California $3,326 21% · 1 recipient
  5. Mississippi $781 5% · 1 recipient

The top 5 of 6 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

157,652

Prescriptions dispensed, refills included

Drug cost

$20,516,709

Paid at the pharmacy, in all

Medicare Part D drugs matched to Vancomycin, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Vancomycin Hcl Similar name 5,465 144,061 $19,465,237
Vancomycin Hcl Vancomycin/Water For Inj (Peg) Similar name 594 11,999 $872,420
Vancomycin Hcl-0.9% Nacl Vancomycin/0.9 % Sod Chloride Similar name 65 1,253 $150,375
Vancomycin Hcl Vancomycin Hcl In 5 % Dextrose Similar name 11 191 $23,238
Vancomycin Vancomycin Hcl In 5 % Dextrose Same name 6 90 $3,683
Vancomycin Hcl-D5w Vancomycin Hcl In 5 % Dextrose Similar name 4 58 $1,755

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 274 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Donald Plummer Internal Medicine AL 361 $47,412 None on record
Pardeep Kumari Infectious Disease FL 315 $38,747 None on record
Patrick Nolan Infectious Disease AL 280 $41,340 None on record
Bradley Fouraker Ophthalmology FL 274 $2,200 None on record
Rajiv Sahni Infectious Disease OH 273 $59,769 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 274 with Patron
24 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record